News

GLS1 immune blockade reduces PAH indications in rat model

Blocking GLS1, an enzyme that drives pro-inflammatory immune macrophages, reduces the signs and symptoms of pulmonary arterial hypertension (PAH) in rats, a study reports. “This study offers a fresh outlook upon understanding the role of macrophages in PAH and provides experimental evidence in developing targeted therapeutic strategies,” the researchers…

TX45 improves heart function, blood flow in PH-HFpEF

A single dose of the investigational therapy TX45 improved heart function and blood flow, or hemodynamics, in people with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), according to interim results from a Phase 1b clinical trial. The part of the study involving PH-HFpEF patients is completely…

Right heart size differs between men and women with PAH: Study

Men with pulmonary arterial hypertension (PAH) have a larger right heart size and worse survival rates than women, independent of body size and functional status, a study reports. Moreover, sex-specific mortality risk thresholds, with higher risk indicated by a larger area of the right pulmonary artery, as measured by…

LungFit PH NO therapy device wins marketing approval in Australia

LungFit PH, a device developed by Beyond Air for administering nitric oxide (NO) therapy, has received marketing approval from the Australian Therapeutic Goods Administration (TGA), which will allow the company to market the device as a Class IIb medical device. NO causes blood vessels to relax and widen, lowering…

Winrevair regimen balances efficacy, safety in PAH: Analysis

The dosing regimen for Winrevair (sotatercept-csrk) is optimal for balancing efficacy and safety in adults with pulmonary arterial hypertension (PAH), an analysis of clinical trial data shows. This regimen is “well-justified based on the totality of the observed safety and efficacy data from Phase 2 and Phase 3…